Pathogenetic concepts of acute coronary syndromes

被引:127
作者
Corti, R [1 ]
Fuster, V [1 ]
Badimon, JJ [1 ]
机构
[1] Mt Sinai Sch Med, Zena & Michael A Wiener Cardiovasc Inst, New York, NY 10029 USA
关键词
D O I
10.1016/S0735-1097(02)02833-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The propensity of plaque to disrupt is a major determinant of future ischemic events. Although they are distinct from one another, the atherosclerotic and thrombotic processes appear to be interdependent and may be integrated under the term "atherothrombosis." It is now clear that plaque composition, rather than the percent stenosis, is a major determinant of plaque vulnerability. Plaque disruption seems to depend on both passive and active phenomena and is not purely mechanical. Inflammation (activation of monocytes/macrophages) is a major determinant of both plaque vulnerability and thrombogenicity as they relate to plaque disruption. In one-third of acute coronary syndromes, there is, however, no plaque disruption but only superficial erosion of a markedly stenotic, fibrotic plaque. In these cases, thrombus formation may be exacerbated by a hyperthrombogenic state present in patients with certain systemic risk factors. The endothelium plays a pivotal role in vascular homeostasis and hemostasis. This dynamic organ regulates blood thrombogenicity as well as contractile, secretory, and mitogenic activities in the vessel wall. Some classic risk factors induce endothetial dysfunction by reducing the bioavailability of nitric oxide, increasing tissue endothelin-1, and activating pro-inflammatory signaling pathways. Vascular hemostasis, which is the maintenance of blood fluidity and vascular integrity, is achieved by counterbalancing the intrinsic clotting tendency of blood. As a consequence of the central role of endothelial cells in hemostatic control, a dysfunctional endothelium will generate a prothrombotic environment favoring development of atherosclerotic lesions and thrombotic complications. (C) 2003 by the American College of Cardiology Foundation.
引用
收藏
页码:7S / 14S
页数:8
相关论文
共 51 条
  • [1] Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction
    Al Suwaidi, J
    Hamasaki, S
    Higano, ST
    Nishimura, RA
    Holmes, DR
    Lerman, A
    [J]. CIRCULATION, 2000, 101 (09) : 948 - 954
  • [2] AMBROSE JA, 1996, SYNDROMES ATHEROSCLE, P105
  • [3] Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques - Effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions
    Badimon, JJ
    Lettino, M
    Toschi, V
    Fuster, V
    Berrozpe, M
    Chesebro, JH
    Badimon, L
    [J]. CIRCULATION, 1999, 99 (14) : 1780 - 1787
  • [4] Mechanisms of disease - Nuclear factor-kappa b - A pivotal transcription factor in chronic inflammatory diseases
    Barnes, PJ
    Larin, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (15) : 1066 - 1071
  • [5] Coronary risk factors and plaque morphology in men with coronary disease who died suddenly
    Burke, AP
    Farb, A
    Malcom, GT
    Liang, YH
    Smialek, J
    Virmani, R
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (18) : 1276 - 1282
  • [6] Corti R, 2001, ANN NY ACAD SCI, V947, P181
  • [7] Corti R, 2000, NEWS PHYSIOL SCI, V15, P125
  • [8] Value or desirability of hemorheological-hemostatic parameter changes as endpoints in blood lipid-regulating trials
    Corti, R
    Badimon, JJ
    [J]. CURRENT OPINION IN LIPIDOLOGY, 2001, 12 (06) : 629 - 637
  • [9] CORTI R, 2001, ANN NY ACAD SCI, V947, P195
  • [10] Pravastatin therapy in hyperlipidemia: Effects on thrombus formation and the systemic hemostatic profile
    Dangas, G
    Badimon, JJ
    Smith, DA
    Unger, AH
    Levine, D
    Shao, JH
    Meraj, P
    Fier, C
    Fallon, JT
    Ambrose, JA
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1999, 33 (05) : 1294 - 1304